Colospan Announces Extended IDE Approval for Its Intraluminal Bypass Device – An Alternative Approach to Diverting Stoma

Colospan, which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved a product line extension to its Intraluminal Bypass Device as part of the company’s investigational device exemption (IDE) application. The line extension offers surgeons size selection for Colospan’s flagship CG-100 product, a device designed to reduce diverting stoma rates in patients undergoing a gastrointestinal resection procedure.